<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_CMUQ_Design skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:CMUQ/Design</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>CMUQ</TITLE></P><NAV class="menu fadeIn"><UL><LI><A href="https://2018.igem.org/Team:CMUQ/Background">
                        Description</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Model">
                        Design</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Demonstrate">
                        Safety</A></LI></UL><LI><A href="https://2018.igem.org/Team:CMUQ/Steps">
                        Steps</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Modelling">
                        Modelling</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/InterLab">
                        Interlab</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Part_Collection">
                        Labbook</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Protocols">
                        Protocols</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Parts">
                        Parts</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Hardware">
                        Hardware</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Software">
                        Software</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Team">Team</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Attributions">Attributions</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Sponsors">Sponsors</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Public_Engagement">    Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Collaborations">
                        Collaborations</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/PublicEngagement">
                        Outreach</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/Gold">
                        Gold Medal</A></LI><LI><A href="https://2018.igem.org/Team:CMUQ/References">
                        References</A></LI></NAV><P><BUTTON onclick="topFunction()" id="myBtn" title="Go to top">Top</BUTTON></P><P><TITLE>CMUQ</TITLE></P><DIV class="fadeIn main-wrapper-first"><DIV class="hero-area relative"><DIV class="banner-area"><DIV class="container FadeIn"><DIV class="row height align-items-center justify-content-center"><DIV class="col-lg-7"><DIV class="banner-content text-center"><H4 class="text-uppercase">CMUQ</H4><H1>Design</H1></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="main-wrapper"><SECTION class="featured-area pt-100 pb-100"><DIV class="container"><DIV class="row align-items-center"><DIV class="col-md-6"><H2><SPAN>CRISPR-Cas12a:</SPAN>  a novel biotechnology replacement to carrier testing 

									
								</H2><P><UL class="unordered-list" style="color:purple"><LI>
									CRISPR-Cas12a (Cpf1) proteins are DNA targeting enzymes that bind and cut DNA based on a guide RNA sequence that is designed to match a target. RNA-guided DNA binding initiates non-specific single-stranded DNA (ssDNA) cleavage activity in Cas12a sufficient to completely degrade both linear and circular ssDNA molecules within minutes. To date, this technology has been used as a genome editing tool; we propose the use of CRISPR cas12a for various diagnostic purposes, specifically for carrier testing to detect heterozygosity in autosomal recessive diseases. 

The indiscriminate degradation of ssDNA will be used to screen for carriers of Sickle Cell Anaemia, one of the most common severe monogenic disorders in the world.  
We will use saliva samples as source of DNA. Target DNA will be amplified by RPA to make it increase the chances of Cas12a finding and binding onto the target, unleashing indiscriminate cutting of single-stranded DNA. This includes the degradation of DNA attached to a fluorescent marker , which will separate the suppressor from the fluorescent molecule which can then be detected by the naked eye. The test will take about 30 min and will be able to replace expensive, time consuming, laboratory and labor intensive methods used currently. This moves us to a field-ready diagnosis technique, that can be used anywhere and custom designed to target any mutation.
</LI></UL></P></DIV></DIV></DIV></SECTION><SECTION class="featured-area pt-100 pb-100"><DIV class="container"><DIV class="row align-items-center"><H2><SPAN>CRISPR-Cas12a:</SPAN>  a novel biotechnology replacement to carrier testing 

									
								</H2><P><UL class="unordered-list" style="color:purple"><LI>
									Up until today, we often hear about how CRISPR technology is revolutionizing medicine in many ways, yet mostly as a genome editing tool. This year, our team proposes the usage of CRISPR-Cas12a for diagnostic purposes, in particular, for carrier testing to detect heterozygosity in autosomal recessive diseases. CRISPR-Cas12a (Cpf1) proteins are DNA targeting enzymes that cut and bind DNA depending on an embedded guide-RNA sequence designed to match a targeted strand of the manipulated DNA. The binding of the guide- RNA sequence with the DNA initiates a non-specific single-stranded DNA (ssDNA) cleavage activity in Cas12a, this is sufficient to completely degrade both linear and circular ssDNA molecules within minutes. The indiscriminate degradation of ssDNA will be mainly used to screen for carriers of Sickle Cell Anaemia, one of the most common severe monogenic disorders in the world. Nevertheless, with minor changes, this technique can be custom designed to target any mutation. Using saliva as the DNA source, the target DNA will be amplified by RPA to increase the chances of Cas12a in finding and binding onto the target strand unleashing indiscriminate cutting of single-stranded DNA. This process, nevertheless, includes the degradation of DNA attached to a fluorescent marker , which will be exposed and detected by the naked eye when the the suppressor gets detached from the fluorescent molecule. This thirty minutes testing method can  not only replace expensive, time consuming, laboratory and labor intensive methods used currently, but it can serve as an introduction to field-ready diagnosis technique which can be used anywhere. 
</LI></UL></P></DIV><DIV class="section-top-border"><H3 class="mb-30">Sickling Test</H3><DIV class="progress-table-wrap"><DIV class="progress-table"><DIV class="table-head"><DIV class="serial">#</DIV><DIV class="country">Item</DIV><DIV class="visit">Sickling Test</DIV><DIV class="percentage">Effectivity</DIV></DIV><DIV class="table-row"><DIV class="serial">01</DIV><DIV class="country"> Specimen</DIV><DIV class="visit">3ml in EDTA tube(may be part of CBC)</DIV></DIV><DIV class="table-row"><DIV class="serial">02</DIV><DIV class="country">Transport Temperature</DIV><DIV class="visit">Ambient ref</DIV></DIV><DIV class="table-row"><DIV class="serial">03</DIV><DIV class="country">Days test is performed</DIV><DIV class="visit">Daily</DIV></DIV><DIV class="table-row"><DIV class="serial">04</DIV><DIV class="country">Turnaround Time</DIV><DIV class="visit">Two working days</DIV></DIV><DIV class="table-row"><DIV class="serial">05</DIV><DIV class="country">Method</DIV><DIV class="visit">Sickling test may be done alone or is done as a part of HB electrolysis</DIV></DIV><DIV class="table-row"><DIV class="serial">06</DIV><DIV class="country">Reference Value</DIV><DIV class="visit">Negative</DIV></DIV><DIV class="table-row"><DIV class="serial">07</DIV><DIV class="country">Interpretation</DIV><DIV class="visit">Positive Sickling Test occurs  in HB S disease, sickle cell trait and HB S/C double heterozygosity. The test is done to confirm sickling or any time when peak is detected by HPLC </DIV></DIV></DIV></DIV></DIV><SECTION class="service-area"><DIV class="container"><DIV class="row"><DIV class="col-md-6"><DIV class="single-service" style="background: url(https://firebasestorage.googleapis.com/v0/b/qsiurp2018-24c40.appspot.com/o/scotty.jpg?alt=media&amp;token=d18a50a4-0ed2-48b5-a149-e187bea17ca7);"><DIV class="overlay overlay-content"><H4 class="text-uppercase">Overlay on Pictures</H4><P>
										Overlay on Pictures
									</P></DIV></DIV></DIV><DIV class="col-md-6"><DIV class="single-service" style="background: url(https://firebasestorage.googleapis.com/v0/b/qsiurp2018-24c40.appspot.com/o/scotty.jpg?alt=media&amp;token=d18a50a4-0ed2-48b5-a149-e187bea17ca7);"><DIV class="overlay overlay-content"><H4 class="text-uppercase">Overlay on Pictures</H4><P>
										Overlay on Pictures
									</P></DIV></DIV></DIV><DIV class="col-md-6"><DIV class="single-service" style="background: url(https://firebasestorage.googleapis.com/v0/b/qsiurp2018-24c40.appspot.com/o/scotty.jpg?alt=media&amp;token=d18a50a4-0ed2-48b5-a149-e187bea17ca7);"><DIV class="overlay overlay-content"><H4 class="text-uppercase">Overlay on Pictures</H4><P>
										Overlay on Pictures
									</P></DIV></DIV></DIV><DIV class="col-md-6"><DIV class="single-service" style="background: url(https://firebasestorage.googleapis.com/v0/b/qsiurp2018-24c40.appspot.com/o/scotty.jpg?alt=media&amp;token=d18a50a4-0ed2-48b5-a149-e187bea17ca7);"><DIV class="overlay overlay-content"><H4 class="text-uppercase">Overlay on Pictures</H4><P class="common-input">
										Overlay on Pictures
									</P></DIV></DIV></DIV></DIV></DIV><FOOTER class="footer-area relative"><DIV class="container"><DIV class="footer-content d-flex flex-column align-items-center"><DIV class="footer"><H4> We Would like to thank our sponsors </H4></DIV></DIV></DIV></FOOTER></SECTION></DIV><UL class="deck"><LI class="deck__item deck__item--Snapchat"><A class="deck__link" href="#"><SPAN class="deck__label">Snapchat</SPAN></A></LI><LI class="deck__item deck__item--Instagram"><A class="deck__link" href="https://www.instagram.com/cmuq.igem/"><SPAN class="deck__label">Instagram</SPAN></A></LI></UL></SECTION></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>